HANSOH PHARMA (03692): Application for a market authorization of Dasatinib Mesylate Tablets accepted by the National Medical Products Administration.

Hans Pharmaceuticals (03692) announced that on February 27, 2026, the group's new drug, sulfamethoxazole Damiertinib tablets in combination with sulfamethoxazole Amitenib tablets (Amelex), has been accepted for a new drug application (NDA) by the China National Medical Products Administration (NMPA). It is used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutation positive and EGFR tyrosine kinase inhibitor (TKI) therapy failure who also have mesenchymal-epithelial transition factor (MET) amplification. Sulfamethoxazole Damieratinib tablet (HS-10241) is an orally administered highly selective c-MET TKI independently developed by the group.